Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ­­Manganese X Energy Corp. (MN) announces its subsidiary, Disruptive Battery Corp., has received positive results from long-term research on fighting pathogens and biofilm
  • The data was collected in conjunction with its US joint partner, PureBiotic Inc., and the research was conducted by the Virginia State University (VSU)
  • VSU’s laboratory was able to produce growths of different types of biofilms required for testing of the PureBiotic AIR HVAC delivery system for the mitigation of infection risks
  • Research has proven that the PureBiotic’s technology can easily and economically control Salmonella, Escherichia coli (E. coli), and other common infections
  • In testing against a wide group of chemical disinfectants currently used in hospitals, the PureBiotic’s formulas proved to be from 78 to 92 per cent more effective than other formulas, depending on the type of infection risk
  • ­­Manganese X Energy Corp. (MN) is unchanged trading at $0.26 per share at 3:34 p.m. ET

­­Manganese X Energy Corp. (MN) announced that its subsidiary has reported positive results from long-term research on fighting pathogens and biofilm.

The data was collected in conjunction with its US joint partner, PureBiotic Inc. The research was conducted by the Virginia State University (VSU).

In VSU’s latest testing, the priority was documenting the risk reduction on an important range of pathogens and biofilm, including COVID-19, by utilizing the PureBiotic mist solution’s effect on biofilm.

It’s considered important to note because the CDC claims biofilm to be responsible for 80 per cent of all infections.

VSU’s laboratory was able to produce growths of different types of biofilms required for testing the PureBiotic AIR HVAC delivery system for the mitigation of infection risks.

The results showed that it was effective in deconstructing the biofilm.

The VSU research team compiled all other testing completed to date by a variety of hospitals, universities and other organizations.

Research has proven that the PureBiotic’s technology can easily and economically control Salmonella, Escherichia coli (E. coli), and other common infections.

It also proved that suppression caused by the product was stable over time.

PureBiotic solutions came to the VSU lab in 2018, when several facilities in Georgia and Indiana were using its products to be tested against E coli.

In testing against a wide group of chemical disinfectants currently used in hospitals, the PureBiotic’s formulas proved to be from 78 to 92 per cent more effective than other formulas, depending on the type of infection risk.

­­Manganese X Energy Corp. (MN) is unchanged trading at $0.26 per share at 3:34 p.m. ET.

More From The Market Herald

" BioVaxys (CSE:BIOV) files patent for pan-sarbecovirus vaccine

BioVaxys Technology (BIOV) has filed a provisional patent application for its viral antigen vaccine platform.

" Datametrex (TSXV:DM) launches smartphone health app

Datametrex AI (DM) subsidiary Medi-Call MD has officially launched a closed beta test for its Medi-Call health app.
Avicanna Inc - CEO, Aras Azadian.

" Avicanna (TSX:AVCN) closes private placement

Avicanna (AVCN) has closed a non-brokered private placement for gross proceeds of approximately $3.9 million.

" Small Pharma (TSXV:DMT) doses first patient in trial

Small Pharma Inc. (DMT) has dosed the first patient of its Phase IIa clinical trial for its lead N,N-dimethyltryptamine candidate, SPL026.